Invention Grant
- Patent Title: Cysteine engineered antibodies and conjugates
-
Application No.: US16787280Application Date: 2020-02-11
-
Publication No.: US11873330B2Publication Date: 2024-01-16
- Inventor: Sunil Bhakta , Jagath R. Junutula
- Applicant: Genentech, Inc.
- Assignee: Genentech, Inc.
- Current Assignee: Genentech, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McNeill Baur PLLC
- The original application number of the division: US15357545 2016.11.21
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/32 ; A61K51/10 ; A61K47/68 ; C07K16/30

Abstract:
Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
Public/Granted literature
- US20200339664A1 Cysteine Engineered Antibodies and Conjugates Public/Granted day:2020-10-29
Information query